BGNE - BeiGene, Ltd.
138.01 +1.72 (1.26%)
After hours: 4:06PM EST
| Previous Close | 143.28 |
| Open | 142.53 |
| Bid | 134.00 x 1400 |
| Ask | 170.00 x 1100 |
| Day's Range | 135.26 - 149.62 |
| 52 Week Range | 105.19 - 220.10 |
| Volume | 527,914 |
| Avg. Volume | 654,109 |
| Market Cap | 8.101B |
| Beta (3Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.81 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 193.92 |
- Zacks•yesterday
BeiGene, Ltd. (BGNE) Is Up 12.82% in One Week: What You Should Know
Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors? Let's find out.
GuruFocus.com•5 days ago6 Stocks Beating the Market
According to the GuruFocus All-in-One Guru Screener, the following stocks have outperformed the Standard & Poor's 500 index over the past 12 months and were bought by gurus during the third quarter. Warning! GuruFocus has detected 6 Warning Signs with BGNE. The share price is 50.86% above its 52-week low and 34.65% below its 52-week high.
- Reuters•8 days ago
BRIEF-Beigene Receives U.S. FDA Breakthrough Therapy Designation For Zanubrutinib
Jan 15 (Reuters) - Beigene Ltd: * RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZANUBRUTINIB IN MANTLE CELL LYMPHOMA Source text for Eikon: Further company coverage:
- MarketWatch•8 days ago
BeiGene drug gets 'breakthrough therapy' designation from FDA
U.S. shares of BeiGene Ltd. rose in the extended session Monday after the biotech drug developer said the Food and Drug Administration will expedite the regulatory process for one of its drugs. BeiGene ADRs rose 4% after hours, following a 4.6% decline to close at $137.55 Monday. The company said the FDA gave a "Breakthrough Therapy" designation to its mantle cell lymphoma treatment, meaning the experimental drug zanubrutinib will get expedited review and guidance from the agency.
- GlobeNewswire•8 days ago
BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- Barrons.com•11 days ago
Engaged Capital Helps Rethink Benchmark Electronics
The goal is to turn the manufacturer into a designer, developer, and value-added partner. Plus, news on 10 other investors’ filings.
- Reuters•19 days ago
BRIEF-Hillhouse Capital Management Ltd Reports 1.7 Pct Stake In Beigene Ltd
Jan 3 (Reuters) - Beigene Ltd: * HILLHOUSE CAPITAL MANAGEMENT, LTD. REPORTS 1.7 PERCENT STAKE IN BEIGENE LTD AS OF JANUARY 1 - SEC FILING * HILLHOUSE CAPITAL MANAGEMENT, LTD. PREVIOUSLY REPORTED 9.29 PERCENT ...
Motley Fool•19 days agoHere's Why BeiGene Is Taking a Hit Today
Shares tumble in response to an industry megamerger.
- GlobeNewswire•20 days ago
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on December 31, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 44,910 American Depositary Shares to 123 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan. The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Market Realist•25 days agoDo Analysts See Any Upside in BeiGene Stock?
Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”
Market Realist•25 days agoUnderstanding BeiGene’s Operational Performance
In its most recent quarter, BeiGene’s (BGNE) selling, general, and administrative expenses rose YoY (year-over-year) to $48.82 million from $15.64 million primarily due to an increased head count.
Market Realist•25 days agoTaking Stock of BeiGene’s Latest Performance
BeiGene Limited (BGNE) is a biopharmaceutical company with a focus on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer. In this series, we’ll explore BeiGene’s financials, valuation, and analyst views.
Market Realist•25 days agoAssessing BeiGene Limited’s Gross Margin Trend
In the third quarter, BeiGene’s (BGNE) total revenue fell YoY (year-over-year) to $54.2 million from $220.21 million. During the quarter, it generated $10.24 million from the US market and $43.96 million from outside the United States. During the comparable period in 2017, it generated $137.4 million from the US market and $82.81 million from outside the United States.
- Motley Fool•29 days ago
Don't Miss Chinese Biotechs
It's not for the faint of heart, but it's hard to oversell just how huge the runway is for the Chinese biotech industry.
- Motley Fool•last month
Our Top Stock Idea in China’s Biotech Revolution
Whether you're in the U.S. or China, immuno-oncology is one of the hottest areas in biotech right now.
- Simply Wall St.•last month
Has BeiGene, Ltd. (NASDAQ:BGNE) Got Enough Cash?
Stocks with market capitalization between $2B and $10B, such as BeiGene, Ltd. (NASDAQ:BGNE) with a size of US$7.9b, do not attract as much attention from the investing community as do Read More...
- Reuters•last month
BRIEF-Beigene Initiates Two Global Phase 3 Front-Line Clinical Trials Of Tislelizumab
Dec 17 (Reuters) - Beigene Ltd: * BEIGENE INITIATES TWO GLOBAL PHASE 3 FRONT-LINE CLINICAL TRIALS OF TISLELIZUMAB, IN PATIENTS WITH GASTRIC CANCER AND IN PATIENTS WITH ESOPHAGEAL CANCER Source text for ...
- GlobeNewswire•last month
BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patients have been enrolled in two global Phase 3 clinical trials of its investigational anti-PD-1 antibody, tislelizumab. “Available data have shown promise for anti-PD-1 antibodies in patients with advanced gastric or gastroesophageal adenocarcinoma and in patients with advanced esophageal carcinoma.
- GlobeNewswire•last month
BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that updated clinical data from an ongoing Phase 1A/1B trial of tislelizumab, an investigational anti-PD-1 antibody, were presented in an oral session and a poster at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress, being held December 13-16 in Geneva, Switzerland. “We continue to be pleased with the results of tislelizumab in solid tumors,” commented Amy Peterson, M.D., Chief Medical Officer, Immuno-Oncology, at BeiGene.
- Insider Monkey•last month
Is BeiGene, Ltd. (BGNE) Going to Burn These Hedge Funds?
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]
- Motley Fool•last month
Here's Why BeiGene Stock Rose 21.7% in November
A third-quarter report and a couple of priority reviews from the China Food and Drug Administration encouraged investors.
- GlobeNewswire•2 months ago
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on November 30, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 46,689 American Depositary Shares to 144 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan. The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- GlobeNewswire•2 months ago
BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the presentation of clinical data from the pivotal Phase 2 trial of its investigational anti-PD-1 antibody, tislelizumab, in Chinese patients with relapsed/refractory (R/R) classical Hodgkin’s lymphoma (cHL). “We set out to address the needs of patients with R/R cHL who have failed to achieve a response or progressed after autologous stem cell transplant (ASCT), or who are not candidates for ASCT, as these patients, unfortunately, have very poor outcomes,” said Jane Huang, M.D., Chief Medical Officer, Hematology, at BeiGene.
- GlobeNewswire•2 months ago
BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. and BEIJING, China, Dec. 01, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
